<DOC>
	<DOCNO>NCT01527305</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness safety paliperidone palmitate schizophrenic inpatient experience recent exacerbation acute schizophrenia ( within past 4 week ) .</brief_summary>
	<brief_title>A Study Evaluate Effectiveness Safety Paliperidone Palmitate Subjects With Acute Schizophrenia</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , prospective ( look forward use periodic observation collect predominantly follow participant enrollment ) , non-comparative multicenter study evaluate effectiveness safety paliperidone palmitate acute schizophrenic participant . This study consist screen phase ( 7 day ) , treatment phase ( 13 week ) , study completion early withdrawal visit . Safety evaluation include adverse event , clinical laboratory test , concomitant medication , physical examination , vital sign , monitor throughout study . The total duration study participation participant approximately 13 week .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Have current diagnosis schizophrenia define Diagnostic Statistical Manual Mental Disorders Version IV ( DSMIV ) Must admit hospital within 4 week prior Screening experience acute exacerbation schizophrenia Have positive negative syndrome scale ( PANSS ) total score equal 60 clinical global impression severity ( CGIS ) score equal 4 ( moderately ill ) Screening Agree protocoldefined method contraception Must medically stable base physical examination , medical history , vital sign , clinical laboratory test perform Screening Have primary active DSMIV Axis I diagnosis schizophrenia Have evidence clinically significant cardiovascular , renal , hepatic , gastrointestinal , neurological , endocrine , metabolic pulmonary disease medical history , clinical laboratory physical examination Have history neuroleptic malignant syndrome Participants risk suicide Have receive clozapine within 1 month prior Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Antipsychotics</keyword>
	<keyword>Paliperidone Palmitate</keyword>
	<keyword>Paliperidone</keyword>
	<keyword>Invega</keyword>
	<keyword>Sustenna</keyword>
	<keyword>Psychotic disorder</keyword>
	<keyword>Psychosis</keyword>
</DOC>